Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2010
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- 17 Sep 2005 New trial record.